Chrysotherapy. A prospective study.
A 4-year prospective clinical study of chrysotherapy was designed to reexamine old beliefs and traditions, and to test potentially new approaches to chrysotherapy. The standard weekly dosage of 50 mg was compared to that based on 1 mg/kg body weight; no significant differences were found. The rapidly absorbed aqueous thiomalate was compared to the slowly absorbed oil repository thioglucose; the latter produced significantly less side effects and an appreciably higher percentage of improvement. Almost half (43%) of nonresponders on standard regimen had a satisfactory clinical response at higher dosage levels without increase in toxicity. Some of these findings vary so much with traditional beliefs and practices that the authors urge caution in their interpretation. But generally speaking these problems are technical and do not detract from the conviction that chrysotherapy is valuable and comparatively safe in the management of rheumatoid arthritis and that it deserves more widespread application in clinical practice.
D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D006051:Aurothioglucose / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006046:Gold / Q000627:therapeutic use*; D006052:Gold Sodium Thiomalate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D011446:Prospective Studies
D006052:Gold Sodium Thiomalate; D006051:Aurothioglucose; D006046:Gold